My take on the medical part is that this is mostly panic from disjointed priorities. Supply and demand (priority driven) affect the medical treatments availabl

My take on the medical part is that this is mostly panic from disjointed priorities. Supply and demand (priority driven) affect the medical treatments available, and the a single cure is a stepping stone to greater efficiency. For example, take COVID immunisation, due to priority we had multiple companies work on these, and the best won, these delivery mechanisms are now updated with new viral variants, but they don't charge as though it's a totally new disease or drugs. In fact the cost is absorbed by the sale of the original and not in the sale of the updated vaccine which is at the same price point or less. Which leads me back to the point, if you run socialised medicine, and you have to choose which medicines offer the greatest return, why would you choose a 1st gen treatment curing one person when a older treatment, which you have infra for, and costs thousands not millions cures in 50% of cases? If you want to fix anything with 1st gen, we need to subsidise the research cost using the same priority as the needs of patients - that gives the demand. Misalignment is just going to cause articles such as this being written, where you don't actually hear about the other things that are a priority being cured. Did you know we have 3 successful treatments for COVID now for example, or in the UK we've started using proton beam therapy after it was famously denied treatment https://en.m.wikipedia.org/wiki/Ashya_King_case https://en.m.wikipedia.org/wiki/Ashya_King_case a few years ago, and now I believe also available within the UK? These are both consequences of a change of priority and normal process, the worry in the article is that a cure isn't being used, which is both 1st gen and probably due to disjoint with the needs of the NHS/socialised medicine, but this would be expected to happen if a company (a single university) wants to carve a well paid niche in an area that has lower priority/demand.